Loading...
Market
Story
DEA Extends Pandemic-Era Telehealth Prescription Rules for Controlled Substances Through December 31, 2025
Nov 15, 2024, 10:57 PM
The U.S. Drug Enforcement Administration (DEA), in collaboration with the Department of Health and Human Services (HHS), has extended the pandemic-era telehealth flexibilities for prescribing controlled substances, including ADHD medications and opioids, for another year. This extension, effective through December 31, 2025, delays the decision on how to unwind these policies to the incoming Trump administration. The extension includes telehealth prescriptions for addiction medications, addressing a contentious issue within the healthcare sector.
View original story
Similar markets
Patients • 25%
Telehealth providers • 25%
Pharmaceutical companies • 25%
Other • 25%
Growth • 25%
Decline • 25%
Stagnation • 25%
Diversification • 25%
Extend waiver • 25%
End waiver • 25%
Modify waiver • 25%
No decision • 25%
Permanent rule allowing telehealth prescribing • 25%
Temporary extension beyond 2025 • 25%
Reversion to pre-COVID rules • 25%
Other • 25%
Current administration • 25%
Incoming administration • 25%
Both administrations • 25%
Neither • 25%
Lobbying • 25%
Legal action • 25%
Public campaigns • 25%
No significant action • 25%
Healthcare • 25%
Energy • 25%
Telecommunications • 25%
Consumer protection • 25%
Hospitals • 25%
Clinics • 25%
Telehealth Services • 25%
Insurance Companies • 25%
Healthcare • 25%
Pharmaceuticals • 25%
Technology • 25%
Consumer Goods • 25%